ArticleJournal of orthopaedic surgery and research2026
miR-211-5p/FOXO3 axis accelerates osteogenic differentiation and fracture healing by mediating Wnt/β-catenin pathway.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a disease closely related to aging, the prevalence and disability rate of osteoporotic fracture (OPF) are on the rise. MicroRNA (miRNA) expression abnormalities are closely linked to various skeletal disorders, yet the regulatory role of miR-211-5p in OPF remains unclear.
objectiveTo investigate the expression patterns of miR-211-5p in OPF and its molecular mechanisms in the osteogenic differentiation and Wnt/β-catenin pathway of BMSCs and MC3T3-E1 cells.
methodsBlood samples were collected from patients with osteoporosis (OP) and OPF who were treated in our hospital, as well as from healthy controls (HC). The levels of miR-211-5p and FOXO3 were quantified by RT-qPCR. The functional activity of the cells was evaluated using CCK-8 assay, flow cytometry, and Western blot techniques, respectively. The targeting relationship was verified by dual-luciferase activity reporter assay and RIP assay.
resultsSerum miR-211-5p was down-regulated in OPF patients, and holds diagnostic potential for identifying such patients. Following treatment, serum miR-211-5p levels increased over time in OPF patients, and osteogenic induction upregulated miR-211-5p level in BMSCs and MC3T3-E1 cells. miR-211-5p directly targeted FOXO3. Overexpression of FOXO3 partially reversed the activation of miR-211-5p mimic on cell viability, osteogenic markers and Wnt/β-catenin pathway effector markers.
conclusionmiR-211-5p promotes bone formation by targeting and inhibiting FOXO3 to activate the Wnt/β-catenin pathway, thereby accelerating fracture healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.